Expression and diagnostic potential of circulating miR-107, miR-134-5p, miR-149-5p, miR-370-3p, and miR-221 in prostate cancer and benign prostatic hyperplasia: A preliminary study

Basit Öğe Kaydı
dc.contributor.authorAkkoç, Ali
dc.contributor.authorSarban, Hamiyet Eciroglu
dc.contributor.authorYildiz, Fatma
dc.contributor.authorGünizi, Ozlem Ceren
dc.contributor.authorUçar, Murat
dc.date.accessioned2026-01-24T12:20:45Z
dc.date.available2026-01-24T12:20:45Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground: MicroRNAs (miRNAs) have shown promise as diagnostic biomarkers for prostate cancer (PCa). This study aimed to evaluate the expression of miR-107, miR-134-5p, miR-149-5p, miR-370-3p, and miR-221 in whole blood to distinguish PCa from benign prostatic hyperplasia (BPH) and potentially reduce unnecessary biopsies. Methods: Whole blood samples were collected from 20 PCa patients, 17 histologically-confirmed BPH patients (all with PSA > 4 ng/mL), and 20 healthy controls over 60 years without symptoms suggesting prostatic disease and PSA < 4 ng/mL. miRNA levels were quantified using qRT-PCR. Diagnostic potential was assessed via correlation analyses with clinical parameters and ROC curve evaluation. Statistical significance was set at p < 0.05. Results: miR-107, miR-134-5p, miR-149-5p, and miR-370-3p were significantly overexpressed in PCa patients compared to BPH (p < 0.0001). ROC analysis identified miR-134-5p (AUC: 0.94) and miR-149-5p (AUC: 0.93) as strong predictors of PCa. Additionally, miR-149-5p showed a positive correlation with PSA levels (r = 0.2627, p < 0.05). Conclusions: This preliminary study demonstrated that miR-107, miR-134-5p, miR-149-5p, and miR-370-3p were significantly overexpressed in PCa patients compared to the BPH group. ROC analysis highlighted their diagnostic potential in distinguishing BPH from PCa. Despite the limited sample size, these findings provide early evidence to guide future research on the diagnostic value of miRNAs in prostate cancer. © 2025, Page Press Publications. All rights reserved.
dc.identifier.doi10.4081/aiua.2025.14585
dc.identifier.issn1124-3562
dc.identifier.issue4
dc.identifier.pmid41258785
dc.identifier.scopus2-s2.0-105025894955
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.4081/aiua.2025.14585
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4563
dc.identifier.volume97
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPage Press Publications
dc.relation.ispartofArchivio Italiano di Urologia e Andrologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260121
dc.subjectBenign prostatic hyperplasia
dc.subjectBiomarker
dc.subjectmiRNA
dc.subjectProstate cancer
dc.subjectPSA
dc.titleExpression and diagnostic potential of circulating miR-107, miR-134-5p, miR-149-5p, miR-370-3p, and miR-221 in prostate cancer and benign prostatic hyperplasia: A preliminary study
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu